Celyad SA is a biopharmaceutical company, specialized in cell therapy. It develops technologies and treatments to treat severe diseases with poor prognosis. The company focuses on Immuno oncology, Cardiology, and Medical devices. Its main product candidates include CAR-T NKR-2, C-Cure. The firm has CYAD-01, CYAD-02, CYAD-03 programs in pipeline. The company owns trademarks and service marks including CELYAD, C-CATH, C_CURE, CATH and C-CATHez and CARDIO 3 BIOSCIENCES. The firm has Cardiology and Corporate operating segments. It derives majority of its revenues from Cardiology segment.
| Website: | www.celyad.com |
| Email: | investors@celyad.com |
| Main Phone: | +32 10394100 |
| Address: | Rue Edouard Belin 2 |
| City / Town: | Mont-Saint-Guibert |
| Country: | BEL |
| Postal Code: | 1435 |
| Exchange: | GREY |
| CEO: | Christian Homsy |
| Employees: | 77 |
| Last Price 27.30 | Change $ 0. | Change % 0.00 | Tick N/A |
| Bid N/A | Bid Size N/A | Ask N/A | Ask Size N/A |
| Open N/A | High N/A | Low N/A | Prev Close 27.30 |
| Last Trade | Volume 0 | 52 Wk Hi 38.75 | 52 Wk Low 27.30 |
| Market Cap 326 mi | Ex-Div Date N/A | Div Rate N/A | Yield N/A |
| Shares 11,942,344.00 | EPS (TTM) -7.39 | PE Ratio N/A | Exchange Greys |
© 2018 Equities
* All dates and time are being displayed in Eastern Standard Time (EST).
